David Kirske

CIK: 0001276750

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (50.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

XFOR

X4 Pharmaceuticals, Inc

Officer

Discretionary Trading P&L

Holdings

Transaction History (6 total)

XFOR
X4 Pharmaceuticals, Inc
Oct 1, 2026
Sale(S)
Direct
11.8K shares at avg. $2.86$34K
XFOR
X4 Pharmaceuticals, Inc
Jun 30, 2026
Sale(S)
Direct
8.5K shares at avg. $4.26$36K
XFOR
X4 Pharmaceuticals, Inc
May 12, 2026
Sale(S)
Direct
17K shares at avg. $4.29$73K
XFOR
X4 Pharmaceuticals, Inc
Oct 29, 2025
Award(A)
Stock Option (right to buy)
Direct
1.6M shares-
XFOR
X4 Pharmaceuticals, Inc
Aug 14, 2025
Award(A)
Direct
193.3K shares-
XFOR
X4 Pharmaceuticals, Inc
Aug 12, 2025
Award(A)
Stock Option (right to buy)
Direct
1.1M shares-

		Type	Shares	Price		Ownership
Oct 1, 2026	XFOR X4 Pharmaceuticals, Inc	Sale(S)	11,767	$2.86	$33,658	Direct
Jun 30, 2026	XFOR X4 Pharmaceuticals, Inc	Sale(S)	8,543	$4.26	$36,428	Direct
May 12, 2026	XFOR X4 Pharmaceuticals, Inc	Sale(S)	16,961	$4.29	$72,820	Direct
Oct 29, 2025	XFOR X4 Pharmaceuticals, Inc	Award(A) Stock Option (right to buy)	1,552,769	-	-	Direct
Aug 14, 2025	XFOR X4 Pharmaceuticals, Inc	Award(A)	193,254	-	-	Direct
Aug 12, 2025	XFOR X4 Pharmaceuticals, Inc	Award(A) Stock Option (right to buy)	1,073,249	-	-	Direct

1-6 of 6 transactions

About KIRSKE DAVID

KIRSKE DAVID (SEC CIK 0001276750) files insider reports with the SEC as Chief Financial Officer of X4 Pharmaceuticals, Inc (XFOR).

Signal8 holds 6 ownership filings by KIRSKE DAVID (1 Form 3, 5 Form 4), filed between Aug 14, 2025 and Oct 5, 2026. Those filings report 6 transactions, from Aug 12, 2025 to Oct 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on KIRSKE DAVID's filings is in BOSTON, MA.

Recent filings by KIRSKE DAVID

Oct 1, 2026: Open-market sale of XFOR shares (Form 4, code S).
Jun 30, 2026: Open-market sale of XFOR shares (Form 4, code S).
May 12, 2026: Open-market sale of XFOR shares (Form 4, code S).
Oct 29, 2025: Grant or award of XFOR derivative securities (Form 4, code A).
Aug 14, 2025: Grant or award of XFOR shares (Form 4, code A).

Other insiders filing for X4 Pharmaceuticals, Inc (XFOR)

Craig Adam R, Executive Chairman
Volpone John, President
Gold Kelly, Director
Bridger Gary, Director
de Craecker Francoise, Director
WYZGA MICHAEL S, Director

How to read Form 4 transaction codes